Evidence map›Paper›PMID 42632837›Full record

ArticleEMBO molecular medicine2026

IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states.

Dimitrios Doultsinos, Ingrid Tomljanovic, Eleftherios Pilalis, Sophia M Abusamra, Mohammed Alshalalfa, Romuald Parmentier, Vidhula Ahire, Imogen E Bridges, Sandy Figiel, Joanna Hester and 19 more

Abstract read
PubMed Publisher
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Dimitrios DoultsinosNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. dimitrios.doultsinos@nds.ox.ac.uk.ORCID http://orcid.org/0000-0003-0873-9873
Ingrid TomljanovicDepartment of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Wytemaweg 80, 3015 CN, Rotterdam, the Netherlands.
Eleftherios Pilalise-NIOS PC, Kallithea-Athens, Greece.
Sophia M AbusamraNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-9588-5005
Mohammed AlshalalfaVeracyte, South San Francisco, CA, USA.
Romuald ParmentierInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Vidhula AhireNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Imogen E BridgesNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Sandy FigielNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Joanna HesterNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-7466-3849
Damien LeachImperial College London, London, UK.
Ashwin NandakumarNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Rensheng WanDepartment of Urology, UCSF, San Francisco, CA, USA.
Yanis ZekriDivision of Oncogenomics, The Netherlands Cancer Insitute, 1066 CX, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-4925-4610
Jichang ZhangFaculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland.
Charlotte L BevanImperial College London, London, UK.ORCID http://orcid.org/0000-0002-7533-0552
Edward O'NeillNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Alastair D LambCentre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0002-2968-7155
Valentine MacauleyNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Jean Phillipe TheurillatFaculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland.
Alfonso UrbanucciCenter for Cancer Eradication Research, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.ORCID http://orcid.org/0000-0003-2931-3652
R Jeffrey KarnesMayo Clinic Dept of Urology, Rochester, MN, USA.
Daniel E SprattUniversity Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Elai DavicioniVeracyte, South San Francisco, CA, USA.
David QuigleyDepartment of Urology, UCSF, San Francisco, CA, USA.
Wilbert ZwartDivision of Oncogenomics, The Netherlands Cancer Insitute, 1066 CX, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-9823-7289
Clementine Le MagnenInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-6084-6054
Aristotelis Chatziioannoue-NIOS PC, Kallithea-Athens, Greece.ORCID http://orcid.org/0000-0003-2078-0844
Ian G MillsNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. ian.mills@nds.ox.ac.uk.ORCID http://orcid.org/0000-0001-5347-5083

Funding

CRIS Cancer Foundation (CRIS Foundation) N/AIllumina Accelerator UK N/AJohn Black Charitable Foundation (JBCF) N/AProstate Cancer Foundation (PCF) N/A
6 · The paper itself

Abstract

Prostate cancer (PCa) is an androgen receptor (AR) driven, high-incidence disease significantly contributing to cancer mortality. To improve treatment outcomes for patients at high risk of metastasis, PCa is in need of better risk stratification at diagnosis. The unfolded protein response (UPR) is an AR-dependent process. However, the impact of the UPR transducer IRE1 on AR-dependent biology and acquired treatment resistance has not been defined. We use pre-clinical models of stress response to describe the impact of IRE1 activity loss on multiple PCa stages and demonstrate its involvement with poor prognosis (RB1 loss), and cell lineage determination (club-like phenotypes). Integrating clinical transcriptomic datasets, we chart IRE1 activity throughout PCa evolution and develop an IRE1 activity signature (IRE1sig1.0) reflecting both tumoral and micro-environmental stress responses. IRE1sig1.0 correlates with tumoral identity, and prognosticates localised and metastatic disease independently from AR activity. Using IRE1sig1.0 as a tool may inform ARSI suitability and guide IRE1 modulation as a novel combination therapeutic in prostate cancer.

Identifiers

PMID42632837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.